Document Detail


Regulatory role of resveratrol on Th17 in autoimmune disease.
MedLine Citation:
PMID:  20708723     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The immune system is balanced with cells that respond to microbes by developing into effector cells and cells that regulate the activity of effector cells. In many immune responses a subset of effector T cells termed Th17 are necessary for complete immunity because the cytokine IL-17 that they produce is critical to elimination of the pathogen. However, the activity of Th17 must be balance with development of regulatory T cells termed T(regs). Usually, when the activity of the effector cells is excessive and not balanced by regulatory cells of the immune system, there is the increased risk for development of autoimmune diseases. Therefore in many autoimmune diseases the activity of Th17 exceeds that of T(regs). Therapeutics for treatment of autoimmune diseases such as Multiple Sclerosis (MS) have focused upon immunosuppression, immunomodulation, or even immunoablation of effector cells such as Th17 followed by hematopoietic stem cell transplantation. Very few approaches have attempted to therapeutically increase immune regulatory cells such as T(regs) in the treatment of autoimmune disease. This review will focus upon the potential `or the use of resveratrol, a natural plant compound that has already been shown to be a potent anti-inflammatory compound, as a complementary therapeutic for MS that increases the activity of T(regs) even though it also increases development of Th17.
Authors:
Thomas M Petro
Related Documents :
11717443 - Vaccination, prevention, and treatment of experimental autoimmune neuritis (ean) by an ...
9890103 - Immunopathogenesis of sle.
9697793 - Intravesical bacille calmette-guérin induces the antiangiogenic chemokine interferon-i...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-08-12
Journal Detail:
Title:  International immunopharmacology     Volume:  11     ISSN:  1878-1705     ISO Abbreviation:  Int. Immunopharmacol.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-28     Completed Date:  2011-06-23     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  100965259     Medline TA:  Int Immunopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  310-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
Affiliation:
Dept. of Oral Biology and the Nebraska Center for Virology, University of Nebraska Medical Center, Lincoln, Nebraska 68583, USA. tpetro@unmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Autoimmune Diseases / drug therapy*,  metabolism
Humans
Immunosuppressive Agents / pharmacology*
Stilbenes / pharmacology*
Th17 Cells / drug effects,  metabolism*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Stilbenes; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Achieving food security in times of crisis.
Next Document:  More neurons for respiratory adaptation: is neurogenesis at work?